CA
NZ
UK
AU
IND
US
Merck (NYSE: MRK) recorded $8.23 billion in oncology revenue for the first quarter, reflecting a 12.1% rise compared with the same period a year earlier. The increase highlights sustained demand for the company’s immuno‑oncology portfolio, anchored by its PD‑1 blocker Keytruda. Market commentators view …
Insmed Incorporated (NASDAQ: INSM) is making strides in its Phase 3 TPIP program, focusing on two critical areas: pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD). The PALM-PAH and PALM-ILD trials are designed to establish the therapy as a …
Enliven Therapeutics has captured investor attention with its experimental oncology treatments, which aim to address unmet needs in rare and aggressive cancers. The company’s focus on precision medicine has fueled optimism, though its programs remain in early-stage testing. Progress in these trials has contributed …
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
Merck (NYSE: MRK) announced that the FDA approved its immunotherapy KEYTRUDA alongside WELIREG for kidney cancer patients at high risk of recurrence after surgery. The decision marks a strategic expansion for Merck’s oncology portfolio, positioning the combination as a frontline option in adjuvant kidney …
Codexis (NASDAQ: CDXS) shareholders finalized their annual meeting decisions, endorsing the company’s proposed board of directors without dissent. The vote reaffirms investor alignment with management’s long-term strategy in the biocatalysis sector. The outcome removes near-term governance uncertainty for the biotech firm.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
Nuvectis Pharma revealed plans to broaden its therapeutic portfolio through a strategic in-licensing deal targeting complement-mediated diseases and oncology. The announcement came during a corporate update call, where leadership emphasized the company’s shift toward high-potential disease areas with limited treatment options. This licensing push …
The biotechnology-focused royalty and licensing company said the notes will be offered in a private placement to qualified institutional buyers under Rule 144A of the Securities Act. Ligand Pharmaceuticals (NASDAQ: LGND) also expects to grant initial purchasers a 13-day option to acquire up to …
The randomized, double-blind, placebo-controlled study evaluated a single 100 µg dose of DT120 (lysergide) orally disintegrating tablet (ODT) in adult patients diagnosed with MDD. The trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in Montgomery–Åsberg Depression Rating Scale …
Please wait processing your request...